An HIV vaccine designed from scratch triggers the rare antibodies HIV usually dodges

HIV has dodged every conventional vaccine for four decades. A team at La Jolla Institute for Immunology, Scripps Research, and IAVI now reports the first vaccine design that drives the rare naive B cells most people never activate toward broadly neutralizing antibodies, in non-human primates, in work published in Nature. The priming immunogen is already in human trials.

The structural problem has been the starting material. HIV's outer surface is dominated by a shape-shifting envelope protein. Conventional vaccines train the immune system to attack the most visible patches, which the virus mutates within months. The rare broadly neutralizing antibodies (bnAbs) that exist in some infected people target conserved sites the virus cannot easily change. Those antibodies only appear after a long, multi-stage B-cell maturation that almost no natural infection and no previous vaccine has successfully induced.

The new design treats that maturation as a curriculum. Each immunogen in the regimen targets a different stage of B-cell development. The first is engineered from scratch to bind the inherited, "germline" antibody receptors carried by the rare naive B cells whose descendants could become broadly neutralizing. Once those rare precursors are activated, subsequent immunogens steer the maturing B cells through mutations that broaden their reach. The team's Nature paper reports that bnAb lineages were generated in at least 50% of immunized animals, with up to 67% neutralization breadth against a reference bnAb panel. Serum bnAb activity developed in 44% of animals, and the strongest responders reached titers the authors expect would protect against diverse HIV isolates.

"This feels like a huge success," said Crotty. Crotty and Scripps co-leader William Schief have been pushing this stepwise germline-targeting strategy through the Consortium for HIV/AIDS Vaccine Development (CHAVD) for 14 years. Crotty has called the project an "Apollo moon mission-type" effort, a multi-institution, multi-decade bet that a designed immunogen, not a stronger copy of a natural one, was the missing piece.

The caveat is structural rather than technical. Every previous HIV vaccine candidate that produced strong bnAb-style responses in primates has failed at the human efficacy stage. The same outcome is possible here, and the field's record warrants caution. What is genuinely new is that the priming immunogen, the first stage of the curriculum that activates the rare naive B cells at all, has already entered Phase 1 human trials, separately from this Nature paper. Earlier 2025 Schief-led human studies tested other stages of the regimen. The current primate data describe the bnAb induction step in non-human primates, not a complete protective regimen in humans.

For now, the result is a working design, not a working vaccine. The team's claim is narrower and stronger: the first vaccine regimen to drive high levels of broadly neutralizing antibodies in non-human primates, in a structured way, with a human trial of the priming immunogen already underway. The next signal will come when the Phase 1 data report, and whether the same curriculum that worked in macaques primes the right human B cells at all.